On July 26-28, Medcaptain made a striking appearance with a series of main In-vitro Diagnostics products and solutions at the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (2022 AACC), held at the McCormick Place Convention Center in Chicago.
Being the world's largest conference of the in-vitro diagnostic industry, the AACC has become one of the most important international academic conferences in the field of clinical testing worldwide and has a significant international influence, attracting over 20,000 international medical professionals and medical device entrepreneurs from over 100 countries worldwide each year.
At 2022 AACC, Medcaptain showcased the cutting-edge science and technology shaping the future of laboratory medicine, including main products like the Fully-automated Chemiluminescence Immunoassay System, Real-time PCR System, Thromboelastography Analyzer, and Fully Automatic Blood Grouping Analyzer, covering coagulation, chemiluminescence, blood typing and molecular diagnostics, as well as comprehensive test items. It has attracted many visitors from around the world, capturing the much-needed disease testing business opportunities.
Medcaptain’s latest in-vitro diagnostics innovations enable clinical laboratories greater flexibility and assurance as they respond to new and existing diagnostic challenges. By minimizing hands-on time, reducing time-to-results, and improving analytical performance, Medcaptain, together with clinical users, is working toward improving patient outcomes.
Over years of operation and development, Medcaptain has won a considerable number of loyal customers in the whole world with its high-quality products and services. In the future, Medcaptain will keep advancing to meet the clinical needs, sharing more medical technologies and providing better healthcare products and solutions for society.
Exhibitor Data Sheet